DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

Our STN: BL 103705/5230

SEP 2 9 2006

Genentech, Incorporated
Attention: Robert L. Garnick, Ph.D.
Senior Vice President, Regulatory Affairs, Quality and Compliance
1 DNA Way, MS# 242
South San Francisco, CA 94080

Dear Dr. Garnick:

Your request to supplement your biologics license application for Rituximab to expand the indication to provide for first-line treatment of follicular, CD20-positive, B-cell non-Hodgkin's lymphoma in combination with CVP chemotherapy has been approved.

We acknowledge your written commitments to provide additional information on an ongoing study and as described in your letter of September 29, 2006, as outlined below:

Postmarketing Study subject to reporting requirements of 21 CFR 601.70:

1. To submit a clinical study report for study M39021, including summary analyses of updated progression-free and overall survival results, updated information on safety that contains a set of all relevant investigator-generated case report forms and narrative summary forms for serious adverse events and documentation of cause of death, and an electronic datasets containing demographic and entry variables, treatment variables, with updated disease status and survival information in a cleaned and locked database using a data cut-off date of March 31, 2007. The dataset will have undergone data cleanup. The report will be submitted by December 31, 2007. The clinical study report will be submitted as a final study report for this PMC if revised labeling is not required. If labeling revisions are required to update the clinical studies section to include substantive new information, the clinical study report will be submitted as an efficacy supplement.

2. To submit a clinical study report for study M39021, including summary analyses of updated progression-free and overall survival results, updated information on safety along with a set of all relevant investigator-generated case report forms and narrative summary forms for serious adverse events and documentation of cause of death, and an electronic datasets containing demographic and entry variables, treatment variables, with updated disease status and survival information in a cleaned and locked database using a data cut-off date of August 31, 2009. The report will be submitted by December 31, 2009. The clinical study report will be submitted as a final study report for this PMC if revised labeling is not required. If labeling revisions are required to update the clinical

include substantive new information, the clinical study report will be submitted as an efficacy supplement.

Please submit all study final reports to your BLA STN BL 103705. Please use the following designators to label prominently all submissions, including supplements, relating to these postmarketing study commitments as appropriate:

- Postmarketing Study Final Report
- Postmarketing Study Correspondence
- Annual Report on Postmarketing Studies

For each postmarketing study subject to the reporting requirements of 21 CFR 601.70, you must describe the status in an annual report on postmarketing studies for this product. The status report for each study should include:

- information to identify and describe the postmarketing commitment,
- the original schedule for the commitment,
- the status of the commitment (i.e. pending, ongoing, delayed, terminated, or submitted),
- an explanation of the status including, for clinical studies, the patient accrual rate (i.e. number enrolled to date and the total planned enrollment), and
- a revised schedule if the study schedule has changed and an explanation of the basis for the revision.

As described in 21 CFR 601.70(e), we may publicly disclose information regarding these postmarketing studies on our Web site (http://www.fda.gov/cder/pmc/default.htm). Please refer to the February 2006 Guidance for Industry: Reports on the Status of Postmarketing Study Commitments - Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997 (see http://www.fda.gov/cder/guidance/5569fnl.htm) for further information.

Pursuant to 21 CFR 201.57(f)(2), patient labeling must be reprinted at the end of the package insert.

Please submit all final printed labeling at the time of use and include implementation information on FDA Form 356h. The final printed labeling (FPL) must be identical to the enclosed labeling text dated September 29, 2006. Marketing product with FPL that is not identical to the approved labeling may render the product misbranded and an unapproved new drug. Please provide a PDF-format electronic copy as well as original paper copies (ten for circulars and five for other labels).

Please submit within 30 days content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at http://www.fda.gov/oc/datacouncil/spl.html, that is identical in content to the enclosed labeling text September 29, 2006. Upon receipt and

verification, we will transmit that version to the National Library of Medicine for posting on the DailyMed website.

In addition, you may wish to submit draft copies of the proposed introductory advertising and promotional labeling with a cover letter requesting advisory comments to the Food and Drug Administration, Center for Drug Evaluation and Research, Division of Drug Marketing, Advertising and Communication, 5901-B Ammendale Road, Beltsville, MD 20705-1266. Final printed advertising and promotional labeling should be submitted at the time of initial dissemination, accompanied by a FDA Form 2253. All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence to support that claim.

Please refer to http://www.fda.gov/cder/biologics/default.htm for important information regarding therapeutic biological products, including the addresses for submissions. Effective August 29, 2005, the new address for all submissions to this application is:

Food and Drug Administration
Center for Drug Evaluation and Research
Therapeutic Biological Products Document Room
5901-B Ammendale Road
Beltsville, Maryland 20705-1266

This information will be included in your biologics license application file.

Sincerely,

Patricia Keegan

Patricia Keegan, M.D.
Director
Division of Biologic Oncology Products
Office of Drug Oncology Products
Center for Drug Evaluation and Research

Enclosure: Revised Labeling